Anti-high mobility group box-1 monoclonal antibody treatment of brain edema induced by influenza infection and lipopolysaccharide

Nobuyuki Nosaka, Kazuki Hatayama, Mutsuko Yamada, Yousuke Fujii, Masato Yashiro, Hidenori Wake, Hirokazu Tsukahara, Masahiro Nishibori, Tsuneo Morishima

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Encephalopathy is a major cause of influenza-associated child death and severe neurological sequelae in Japan, highlighting the urgent need for new therapeutic strategies. In this study, we evaluated the effects of anti-high mobility group box-1 monoclonal antibody (α-HMGB1) treatment on brain edema induced by influenza A virus (IAV) and lipopolysaccharide in 4-week-old BALB/c female mice. The results showed that administration of 7.5 mg/kg α-HMGB1 1 h after IAV (A/Puerto Rico/8/34) inoculation significantly alleviated brain edema at 48 h after IAV inoculation, as confirmed by the suppression of Evans Blue dye leakage and matrix metallopeptidase-9 mRNA expression in the brain. Moreover, we also observed suppression of oxidative stress and different cytokines in IAV-inoculated mice. The expression of plasminogen activator inhibitor-1 was also attenuated following treatment with α-HMGB1. Notably, α-HMGB1 treatment had no effect on virus propagation in the lung. In summary, anti-HMGB1 treatment may improve the prognosis in cases with influenza-associated encephalopathy by attenuating brain edema and reducing the inflammatory responses induced by HMGB1.

Original languageEnglish
Pages (from-to)1192-1198
Number of pages7
JournalJournal of Medical Virology
Volume90
Issue number7
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

HMGB1 Protein
Brain Edema
Human Influenza
Influenza A virus
Lipopolysaccharides
Monoclonal Antibodies
Infection
Brain Diseases
Therapeutics
Puerto Rico
Evans Blue
Plasminogen Activator Inhibitor 1
Metalloproteases
Japan
Oxidative Stress
Coloring Agents
Cytokines
Viruses
Lung
Messenger RNA

Keywords

  • brain edema
  • encephalopathy
  • high mobility group box-1
  • influenza virus
  • monoclonal antibody

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Anti-high mobility group box-1 monoclonal antibody treatment of brain edema induced by influenza infection and lipopolysaccharide. / Nosaka, Nobuyuki; Hatayama, Kazuki; Yamada, Mutsuko; Fujii, Yousuke; Yashiro, Masato; Wake, Hidenori; Tsukahara, Hirokazu; Nishibori, Masahiro; Morishima, Tsuneo.

In: Journal of Medical Virology, Vol. 90, No. 7, 01.07.2018, p. 1192-1198.

Research output: Contribution to journalArticle

@article{9b3f5d0845fe466cb6bf18bd95ba0f94,
title = "Anti-high mobility group box-1 monoclonal antibody treatment of brain edema induced by influenza infection and lipopolysaccharide",
abstract = "Encephalopathy is a major cause of influenza-associated child death and severe neurological sequelae in Japan, highlighting the urgent need for new therapeutic strategies. In this study, we evaluated the effects of anti-high mobility group box-1 monoclonal antibody (α-HMGB1) treatment on brain edema induced by influenza A virus (IAV) and lipopolysaccharide in 4-week-old BALB/c female mice. The results showed that administration of 7.5 mg/kg α-HMGB1 1 h after IAV (A/Puerto Rico/8/34) inoculation significantly alleviated brain edema at 48 h after IAV inoculation, as confirmed by the suppression of Evans Blue dye leakage and matrix metallopeptidase-9 mRNA expression in the brain. Moreover, we also observed suppression of oxidative stress and different cytokines in IAV-inoculated mice. The expression of plasminogen activator inhibitor-1 was also attenuated following treatment with α-HMGB1. Notably, α-HMGB1 treatment had no effect on virus propagation in the lung. In summary, anti-HMGB1 treatment may improve the prognosis in cases with influenza-associated encephalopathy by attenuating brain edema and reducing the inflammatory responses induced by HMGB1.",
keywords = "brain edema, encephalopathy, high mobility group box-1, influenza virus, monoclonal antibody",
author = "Nobuyuki Nosaka and Kazuki Hatayama and Mutsuko Yamada and Yousuke Fujii and Masato Yashiro and Hidenori Wake and Hirokazu Tsukahara and Masahiro Nishibori and Tsuneo Morishima",
year = "2018",
month = "7",
day = "1",
doi = "10.1002/jmv.25076",
language = "English",
volume = "90",
pages = "1192--1198",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Anti-high mobility group box-1 monoclonal antibody treatment of brain edema induced by influenza infection and lipopolysaccharide

AU - Nosaka, Nobuyuki

AU - Hatayama, Kazuki

AU - Yamada, Mutsuko

AU - Fujii, Yousuke

AU - Yashiro, Masato

AU - Wake, Hidenori

AU - Tsukahara, Hirokazu

AU - Nishibori, Masahiro

AU - Morishima, Tsuneo

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Encephalopathy is a major cause of influenza-associated child death and severe neurological sequelae in Japan, highlighting the urgent need for new therapeutic strategies. In this study, we evaluated the effects of anti-high mobility group box-1 monoclonal antibody (α-HMGB1) treatment on brain edema induced by influenza A virus (IAV) and lipopolysaccharide in 4-week-old BALB/c female mice. The results showed that administration of 7.5 mg/kg α-HMGB1 1 h after IAV (A/Puerto Rico/8/34) inoculation significantly alleviated brain edema at 48 h after IAV inoculation, as confirmed by the suppression of Evans Blue dye leakage and matrix metallopeptidase-9 mRNA expression in the brain. Moreover, we also observed suppression of oxidative stress and different cytokines in IAV-inoculated mice. The expression of plasminogen activator inhibitor-1 was also attenuated following treatment with α-HMGB1. Notably, α-HMGB1 treatment had no effect on virus propagation in the lung. In summary, anti-HMGB1 treatment may improve the prognosis in cases with influenza-associated encephalopathy by attenuating brain edema and reducing the inflammatory responses induced by HMGB1.

AB - Encephalopathy is a major cause of influenza-associated child death and severe neurological sequelae in Japan, highlighting the urgent need for new therapeutic strategies. In this study, we evaluated the effects of anti-high mobility group box-1 monoclonal antibody (α-HMGB1) treatment on brain edema induced by influenza A virus (IAV) and lipopolysaccharide in 4-week-old BALB/c female mice. The results showed that administration of 7.5 mg/kg α-HMGB1 1 h after IAV (A/Puerto Rico/8/34) inoculation significantly alleviated brain edema at 48 h after IAV inoculation, as confirmed by the suppression of Evans Blue dye leakage and matrix metallopeptidase-9 mRNA expression in the brain. Moreover, we also observed suppression of oxidative stress and different cytokines in IAV-inoculated mice. The expression of plasminogen activator inhibitor-1 was also attenuated following treatment with α-HMGB1. Notably, α-HMGB1 treatment had no effect on virus propagation in the lung. In summary, anti-HMGB1 treatment may improve the prognosis in cases with influenza-associated encephalopathy by attenuating brain edema and reducing the inflammatory responses induced by HMGB1.

KW - brain edema

KW - encephalopathy

KW - high mobility group box-1

KW - influenza virus

KW - monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=85044764001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044764001&partnerID=8YFLogxK

U2 - 10.1002/jmv.25076

DO - 10.1002/jmv.25076

M3 - Article

C2 - 29573352

AN - SCOPUS:85044764001

VL - 90

SP - 1192

EP - 1198

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 7

ER -